Uveitic Glaucoma: Long-term Clinical Outcome and Risk Factors for Progression.

Autor:	Sharon, Yael, Friling, Ronit, Luski, Moshe, Campoverde, Belén Quizhpe, Amer, Radgonde, Kramer, Michal
Předmět:	GLAUCOMA UVEITIS INTRAOCULAR pressure IMMUNOREGULATION HEALTH outcome assessment DISEASE progression DISEASE risk factors GLAUCOMA diagnosis THERAPEUTIC use of glucocorticoids COMPARATIVE studies LONGITUDINAL method RESEARCH methodology MEDICAL cooperation RESEARCH VISUAL acuity VISUAL fields EVALUATION research TREATMENT effectiveness RETROSPECTIVE studies OCULAR hypertension DISEASE complications DIAGNOSIS
Zdroj:	Ocular Immunology & Inflammation; Dec2017, Vol. 25 Issue 6, p740-747, 8p
Abstrakt:	Purpose: To study the long-term clinical outcomes of uveitic glaucoma and to identify risk factors for progression.Methods: Retrospective study of uveitic glaucoma patients in two tertiary medical centers in 2003-2015. Patient- and disease-related data was retrieved. Clinical parameters and visual fields measured at predetermined time points were recorded. Outcome measures included maintaining intraocular pressure ≤21 mmHg and preserving visual fields.Results: Included were 34 patients (53 eyes), with a mean follow-up of 7 years. Idiopathic anterior uveitis and open-angle glaucoma were most common. In total, 62% of eyes were steroid responders. Higher IOP was associated with posterior synechiae, peripheral-anterior synechiae, steroidal, and immunomodulatory therapy (p<0.05). Glaucomatous field defects developed in 49%, with most showing no progression, despite elevation of cup-to-disc ratio (p<0.05).Conclusions: Chronic severe uveitis, expressed by structural complications and immunomodulatory therapy, was associated with high IOP and the need for more IOP lowering medications, but was unrelated to glaucomatous damage. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.